Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 20.8 mg - tablet, film coated - excipient ingredients: magnesium stearate; magnesium oxide; lactose monohydrate; crospovidone; microcrystalline cellulose; purified water; titanium dioxide; hypromellose; triacetin; iron oxide red - rosuvastatin pcor should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events rosuvastatin pcor is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin pcor is indicated to: ? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia rosuvastatin pcor is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with rosuvastatin pcor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 41.6 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; crospovidone; microcrystalline cellulose; magnesium oxide; purified water; titanium dioxide; hypromellose; triacetin; iron oxide red - rosuvastatin pcor should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events rosuvastatin pcor is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin pcor is indicated to: ? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia rosuvastatin pcor is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with rosuvastatin pcor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - rosuvastatin calcium, quantity: 41.68 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; crospovidone; microcrystalline cellulose; light magnesium oxide; titanium dioxide; lactose monohydrate; hypromellose; sunset yellow fcf aluminium lake; triacetin; brilliant blue fcf aluminium lake; allura red ac aluminium lake - rosuvastatin lupin should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events rosuvastatin lupin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin lupin is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia rosuvastatin lupin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with rosuvastatin lupin , secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - rosuvastatin calcium, quantity: 20.84 mg - tablet, film coated - excipient ingredients: lactose; crospovidone; magnesium stearate; light magnesium oxide; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - rosuvastatin lupin should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events rosuvastatin lupin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin lupin is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia rosuvastatin lupin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with rosuvastatin lupin , secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - rosuvastatin calcium, quantity: 5.21 mg - tablet, film coated - excipient ingredients: crospovidone; lactose; magnesium stearate; microcrystalline cellulose; light magnesium oxide; hypromellose; triacetin; titanium dioxide; lactose monohydrate; iron oxide yellow - rosuvastatin lupin should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events rosuvastatin lupin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin lupin is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia rosuvastatin lupin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with rosuvastatin lupin , secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - rosuvastatin calcium, quantity: 10.42 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; crospovidone; microcrystalline cellulose; light magnesium oxide; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - rosuvastatin lupin should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events rosuvastatin lupin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin lupin is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia rosuvastatin lupin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with rosuvastatin lupin , secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

american health packaging - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - rosuvastatin 5 mg - rosuvastatin tablets are indicated as adjunctive therapy to diet to reduce elevated total-c, ldl-c, apob, nonhdl-c, and triglycerides and to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia. lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate. rosuvastatin tablets are indicated as an adjunct to diet to: - reduce total-c, ldl-c and apob levels in children and adolescents 8 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: ldl-c >190 mg/dl, or >160 mg/dl along with a positive family history of premature cardiovascular disease (cvd) or two or more other cvd risk factors. pediatric use information for patients 7 to 17 years of age is approved for astrazeneca’s crestor (rosuvastatin calcium) tablets. however, due to astrazeneca’s marketing exclusivity r

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - rosuvastatin 5 mg - rosuvastatin tablets are indicated: •           to reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (cv) disease based on age, hscrp ≥2 mg/l, and at least one additional cv risk factor. •           as an adjunct to diet to: o   reduce ldl-c in adults with primary hyperlipidemia. o   reduce low-density lipoprotein cholesterol (ldl-c) and slow the progression of atherosclerosis in adults. o   reduce ldl-c in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (hefh). •    as an adjunct to other ldl-c-lowering therapies, or alone if such treatments are unavailable, to reduce ldl-c in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (hofh). - as an adjunct to diet for the treatment of adults with: o      primary dysbetalipoproteinemia. o      hypertriglyceridemia. rosuvastatin i

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

msn laboratories private limited - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - rosuvastatin 5 mg - rosuvastatin tablets are indicated: - to reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (cv) disease based on age, hscrp ≥2 mg/l, and at least one additional cv risk factor. - as an adjunct to diet to: o reduce ldl-c in adults with primary hyperlipidemia. o reduce low-density lipoprotein cholesterol (ldl-c) and slow the progression of atherosclerosis in adults. o reduce ldl-c in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (hefh). - as an adjunct to other ldl-c-lowering therapies, or alone if such treatments are unavailable, to reduce ldl-c in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (hofh). - as an adjunct to diet for the treatment of adults with: o primary dysbetalipoproteinemia. o hypertriglyceridemia. rosuvastatin calci

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

a-s medication solutions - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - rosuvastatin 10 mg - pediatric use information for patients 7 to 17 years of age is approved for astrazeneca’s crestor (rosuvastatin calcium) tablets. however, due to astrazeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. rosuvastatin calcium tablets are indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. rosuvastatin calcium tablets are indicated as an adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (type iii hyperlipoproteinemia). rosuvastatin calcium tablets are indicated as adjunctive therapy to other lipid-lowering treatments (e.g., ldl apheresis) or alone if such treatments are unavailable to reduce ldl-c, total-c, and apob in adult patients with homozygous familial hypercholesterolemia. rosuvastatin calcium tablets have not been studied in fredrickson type i and v dyslipidemias. rosuvastatin calcium tablets are contraindicated in the following conditions: rosuvastatin calcium tab